A randomised trial of adjuvant procarbazine, CCNU, vincristine chemotherapy in patients with highly anaplastic oligodendroglioma (BR11) - EORTC

Phase 3

Completed

• Conditions: Brain tumour; Cancer; Anaplastic oligodendroglioma, brain tumours

• Registration Number: ISRCTN32891249
• Lead Sponsor: Medical Research Council (MRC) (UK)

Brief Summary

2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16782911 results 2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18089866 results 2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18089867 results 2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/19224764 results

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2000-04-06
• Study Completion: 2002-03-01
• Last Update Posted: 8 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 368

Inclusion Criteria

1. Newly diagnosed anaplastic oligodendroglioma, or oligoastrocytoma (with 25% or more oligodendral elements); including patients treated with surgery only for a low grade oligoastrocytoma or oligodendroglioma who are diagnosed with anaplastic tumour at the time of recurrence
2. At least three of five histologic anaplastic features: high cellularity, nuclear abnormalities, mitoses, endothelial abnormalities and necrosis, as diagnosed by the local pathologist

Exclusion Criteria

Does not meet inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival

Secondary Outcome Measures

Name	Time	Method
Progression-free survival, quality of life including neurotoxicity and neuropsychological impairments